Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $9,115 | 431 | 99.5% |
| Education | $42.32 | 6 | 0.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $1,742 | 86 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $1,216 | 53 | $0 (2023) |
| Bayer Healthcare Pharmaceuticals Inc. | $1,004 | 33 | $0 (2023) |
| Amgen Inc. | $974.49 | 47 | $0 (2022) |
| Lilly USA, LLC | $598.22 | 32 | $0 (2023) |
| SANOFI-AVENTIS U.S. LLC | $425.09 | 24 | $0 (2022) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $367.83 | 15 | $0 (2022) |
| Amarin Pharma Inc. | $320.69 | 14 | $0 (2022) |
| GlaxoSmithKline, LLC. | $303.77 | 29 | $0 (2022) |
| Radius Health, Inc. | $272.67 | 10 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $218.67 | 10 | Abbott Laboratories ($38.37) |
| 2022 | $2,256 | 68 | Bayer HealthCare Pharmaceuticals Inc. ($664.17) |
| 2021 | $1,718 | 67 | Novo Nordisk Inc ($425.63) |
| 2020 | $1,156 | 62 | AstraZeneca Pharmaceuticals LP ($308.41) |
| 2019 | $429.58 | 19 | Radius Health, Inc. ($123.15) |
| 2018 | $1,592 | 93 | Amgen Inc. ($251.74) |
| 2017 | $1,788 | 118 | AstraZeneca Pharmaceuticals LP ($317.12) |
All Payment Transactions
437 individual payment records from CMS Open Payments — Page 1 of 18
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/25/2023 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $13.92 | General |
| Category: Cardio-renal | ||||||
| 10/17/2023 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $17.50 | General |
| Category: Diabetes Care | ||||||
| 07/04/2023 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $20.87 | General |
| Category: Diabetes Care | ||||||
| 04/12/2023 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $24.29 | General |
| Category: Cardio-renal | ||||||
| 04/05/2023 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $18.94 | General |
| Category: Diabetes | ||||||
| 03/01/2023 | GENZYME CORPORATION | ENJAYMO (Biological), CABLIVI | Food and Beverage | In-kind items and services | $36.93 | General |
| Category: Hematology | ||||||
| 02/13/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $24.87 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 02/02/2023 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $26.21 | General |
| Category: Diabetes | ||||||
| 01/27/2023 | Aadi Bioscience, Inc. | Fyarro (Drug) | Food and Beverage | In-kind items and services | $21.43 | General |
| Category: Cancer | ||||||
| 01/18/2023 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $13.71 | General |
| Category: Diabetes | ||||||
| 12/07/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $26.23 | General |
| Category: DIABETES | ||||||
| 12/02/2022 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $10.16 | General |
| Category: Diabetes | ||||||
| 11/18/2022 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $17.51 | General |
| Category: Cardio-renal | ||||||
| 11/18/2022 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $2.00 | General |
| Category: Cardio-renal | ||||||
| 11/09/2022 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $21.07 | General |
| Category: Diabetes | ||||||
| 11/03/2022 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $123.56 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/02/2022 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $17.98 | General |
| Category: RESPIRATORY | ||||||
| 10/31/2022 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $5.65 | General |
| Category: Diabetes | ||||||
| 10/28/2022 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $17.85 | General |
| Category: Respiratory | ||||||
| 10/20/2022 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $28.66 | General |
| Category: Cardio-renal | ||||||
| 10/19/2022 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $23.18 | General |
| Category: Endocrinology | ||||||
| 10/12/2022 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $24.75 | General |
| Category: Diabetes | ||||||
| 10/04/2022 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | Cash or cash equivalent | $110.00 | General |
| Category: Diabetes | ||||||
| 10/04/2022 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $12.29 | General |
| Category: Cardio-renal | ||||||
| 10/03/2022 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $24.25 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 444 | 592 | $161,153 | $24,220 |
| 2022 | 7 | 543 | 797 | $215,469 | $36,245 |
| 2021 | 9 | 657 | 972 | $213,289 | $83,824 |
| 2020 | 9 | 620 | 907 | $164,893 | $59,016 |
All Medicare Procedures & Services
31 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 158 | 261 | $87,174 | $12,471 | 14.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 113 | 147 | $34,839 | $6,146 | 17.6% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 108 | 108 | $36,936 | $4,892 | 13.2% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 23 | 23 | $1,150 | $468.51 | 40.7% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 13 | 13 | $494.00 | $137.06 | 27.7% |
| 96127 | Assessment of emotional or behavioral problems | Office | 2023 | 29 | 40 | $560.00 | $105.59 | 18.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 190 | 397 | $132,598 | $20,403 | 15.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 107 | 153 | $36,261 | $6,395 | 17.6% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 110 | 110 | $37,620 | $5,435 | 14.4% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2022 | 36 | 36 | $6,463 | $2,467 | 38.2% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 37 | 37 | $1,295 | $1,205 | 93.1% |
| 96127 | Assessment of emotional or behavioral problems | Office | 2022 | 49 | 50 | $700.00 | $177.25 | 25.3% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 14 | 14 | $532.00 | $162.15 | 30.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 180 | 375 | $98,250 | $37,331 | 38.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 183 | 301 | $55,384 | $18,313 | 33.1% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 125 | 125 | $33,625 | $17,945 | 53.4% |
| 99496 | Transitional care management services, highly complexity, requiring face-to-face visits within 7 days of discharge | Office | 2021 | 12 | 13 | $7,423 | $3,166 | 42.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 21 | 22 | $8,008 | $2,942 | 36.7% |
| 90662 | Vaccine for influenza for injection into muscle, split virus, preservation free | Office | 2021 | 35 | 35 | $6,793 | $2,284 | 33.6% |
| G0444 | Annual depression screening, 15 minutes | Office | 2021 | 47 | 47 | $1,880 | $978.07 | 52.0% |
| G0008 | Administration of influenza virus vaccine | Office | 2021 | 36 | 36 | $1,260 | $677.88 | 53.8% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2021 | 18 | 18 | $666.00 | $186.71 | 28.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 128 | 234 | $54,756 | $19,058 | 34.8% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 186 | 363 | $58,806 | $17,952 | 30.5% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2020 | 137 | 137 | $34,250 | $17,057 | 49.8% |
About Dr. Gerald Soon, M.D
Dr. Gerald Soon, M.D is a Internal Medicine healthcare provider based in Honolulu, Hawaii. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1588772123.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gerald Soon, M.D has received a total of $9,158 in payments from pharmaceutical and medical device companies, with $218.67 received in 2023. These payments were reported across 437 transactions from 30 companies. The most common payment nature is "Food and Beverage" ($9,115).
As a Medicare-enrolled provider, Soon has provided services to 2,264 Medicare beneficiaries, totaling 3,268 services with total Medicare billing of $203,304. Data is available for 4 years (2020–2023), covering 31 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Location Honolulu, HI
- Active Since 08/25/2006
- Last Updated 07/08/2007
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1588772123
Products in Payments
- Kerendia (Drug) $1,004
- FARXIGA (Drug) $892.84
- Ozempic (Drug) $685.99
- JARDIANCE (Drug) $398.47
- Rybelsus (Drug) $390.53
- Prolia (Biological) $387.88
- Vascepa (Drug) $320.69
- RYBELSUS (Drug) $299.04
- Tymlos (Biological) $272.67
- Victoza (Drug) $270.30
- PRALUENT (Drug) $212.77
- XARELTO (Drug) $209.07
- Aimovig (Biological) $194.76
- TRULICITY (Drug) $194.27
- NEXLETOL (Drug) $187.72
- MOUNJARO (Drug) $186.31
- BREZTRI (Drug) $155.64
- EVENITY (Biological) $136.81
- EUCRISA (Drug) $133.34
- JANUVIA (Drug) $125.68
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Honolulu
Dr. Alan Parsa, M.d, M.D
Internal Medicine — Payments: $747,055
Dr. Keith Woo, M.d, M.D
Internal Medicine — Payments: $183,455
Dr. Charles Zerez, M.d, M.D
Internal Medicine — Payments: $97,493
Joshua Tan, M.d, M.D
Internal Medicine — Payments: $94,447
James Lumeng, M.d, M.D
Internal Medicine — Payments: $66,956
Jose Deleon, M.d, M.D
Internal Medicine — Payments: $55,692